NeuroDerm Overview
NeuroDerm specializes in integrating proprietary pharmaceutical formulations, state-of-the-art delivery system, and digital health solutions with the aim of reducing disease burden and improving the quality of life of patients and their families. NeuroDerm’s flagship product ND0612 is currently in late stage development for Parkinson’s disease patients experiencing motor fluctuations. Its system for self-administered continuous subcutaneous infusion of the gold standard levodopa/carbidopa, was designed specifically to be a user-friendly system for people with Parkinson's disease, to maintain steady therapeutic levodopa plasma concentrations for the purpose of improving fluctuations, that is, reducing patients’ "OFF" time without increasing troublesome dyskinesia. Its tailored solution potentially offers sustained relief (compared to oral immediate-release levodopa/carbidopa treatments) and empowers patients and their families to regain control of their lives with greater daily-life predictability and independence.
Cumulative Funding Raised Over Time ($)
Latest News
growth-positive
NeuroDerm Announces Highly Positive Results from the Pivotal Phase III BouNDless Trial Evaluating ND0612 in Parkinson's Disease Patients with Motor Fluctuations
NeuroDerm Ltd., a subsidiary of Mitsubishi Tanabe Pharma Corporation, announced positive results from the Phase III BouNDless trial of ND0612, a continuous 24-hour infusion of levodopa/carbidopa for Parkinsons Disease patients with motor fluctuations. The trial met its primary endpoint of Good ON time, demonstrating superior efficacy over oral levodopa/carbidopa. Only 6.3% of patients discontinued the trial, with 5.5% due to adverse events. The results suggest ND0612 could be an effective treatment strategy for Parkinsons disease patients with motor fluctuations. Submissions to regulatory authorities are anticipated in the United States this year and later in the European Union.
Customers
growth-positive
Phase 3 Clinical Trial Evaluating Continuous Subcutaneous Carbidopa/Levodopa (ND0612) Initiated In The United States For Parkinson's Disease With Motor Fluctuations
Mitsubishi Tanabe Pharma America, Inc. has announced the initiation of the Phase 3 BouNDless study to investigate the efficacy of ND0612, a potential non-surgical continuous treatment for Parkinsons disease. The study aims to compare the treatment to oral immediate-release carbidopa/levodopa (CD/LD) in patients experiencing motor fluctuations. The company recognizes the limitations of current therapeutic options and hopes to develop a treatment that stabilizes CD/LD plasma levels and alleviates motor fluctuations. The clinical development of ND0612 is being led by NeuroDerm, and if regulatory approval is obtained, Mitsubishi Tanabe Pharma America intends to commercialize the therapy in the U.S. The study design will be presented at an upcoming conference. Mitsubishi Tanabe Pharma America is a wholly-owned subsidiary of Mitsubishi Tanabe Pharma Corporation.
Customers
growth-positive
NeuroDerm Enters Definitive Agreement to be Acquired by Mitsubishi Tanabe Pharma Corporation for US$1.1 Billion in Cash
NeuroDerm Ltd. has signed a definitive agreement to be acquired by Mitsubishi Tanabe Pharma Corporation for $39 per share in cash. The transaction, which has received unanimous approval by NeuroDerms Board of Directors, implies an equity value of approximately $1.1 billion. The acquisition is expected to benefit NeuroDerms shareholders and Parkinsons disease patients by making new therapies available more rapidly. The transaction is subject to approval by NeuroDerms shareholders and regulatory authorities, and is expected to close in the fourth quarter of 2017. Centerview Partners, LLC is acting as financial advisor to NeuroDerm.
Acquisition
growth-positive
Neuroderm mulls several acquisition offers
Neuroderm, an Israeli drug delivery company, saw a 14% increase in its share price following reports that it was considering acquisition offers. The company has received several offers and has begun the initial examination process with potential buyers. Neuroderm has a market cap of $658 million and is seeking a substantial premium on its market price. The potential buyers are pharma companies in the neurology sector. Neuroderm has developed a unique method of delivering drugs through the skin and its leading products are new formulations of Levodopa. The company obtained an exemption from multi-center Phase III trials for registering its product from the US FDA. Neuroderms main shareholders include Sequoia Capital, Omrix Biopharmaceuticals founder Robert Taub, former GE executive Uwe Wascher, Prof. Shmuel Cabilly, Redmile Capital Fund, and CEO Oded Lieberman.
Acquisition
growth-positive
Neuroderm jumps on successful trial results
Neuroderm has announced success in an open trial of its drug for treatment of Parkinsons Disease. The trial results showed that the companys product reduces the patients average off time from 5.5 hours a day before the trial, after receiving the currently accepted treatment, to 2.7 hours after treatment with the drug. The companys share price jumped 22% on the news, boosting Neuroderms market cap to $749 million, a record for the company and the highest market cap for a purely Israeli biomed company currently listed on Nasdaq. Neuroderm has since conducted two offerings, each at a higher price than its predecessor. The company is changing its development plan for Europe based on the trial results.
Customers
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $63.5M |
| Last funding | $45M |
| Stage | Acquired |
| Rounds | 3 |
| Investors | 2 |
Team Members
4
Employees: 51-200
Web & Social Links
| Website | neuroderm.com |
| Careers | Careers page |
Locations
Prof. Haim Pekeris 3, Rehovot, Israel
Photos & Videos
1 item(s)
